Tirzepatide: A Research Overview

Tirzepatide is described in the literature as a synthetic 39-amino-acid peptide based on the native glucose-dependent insulinotropic polypeptide (GIP) sequence that acts as a unimolecular dual agonist at both the GIP and glucagon-like peptide-1 (GLP-1) receptors [1]. The rationale reviewed for this design came from human physiology work indicating that co-infusion of GLP-1 and GIP produced a greater insulin and glucagonostatic response than separate administration of either hormone, prompting the development of so-called 'twincretin' agonists [1]. Reviews of the early development programme summarised preclinical work together with phase 1 and phase 2 human trials, reporting glucose lowering and body-weight reduction with an adverse-event pattern described as comparable to established GLP-1 receptor agonists [1][2]. In the phase 3 SURPASS programme in adults with type 2 diabetes, a review of the trials supporting regulatory approval reported greater reductions in glycated haemoglobin and body weight than placebo and than active comparators across the studied populations, with dose-ranging arms included in each trial [3]. A systematic review and meta-analysis of randomised controlled trials examining incretin-based agents added to basal insulin in uncontrolled type 2 diabetes pooled eleven trials and reported reductions in glycated haemoglobin and fasting plasma glucose, a higher proportion of participants reaching a glycated haemoglobin target below 7%, and body-weight reduction, without an increased relative risk of hypoglycaemia; the authors noted that weight reduction in the tirzepatide arms exceeded that observed with GLP-1 receptor agonist arms [4]. For body-weight endpoints in people with overweight or obesity, a scoping review of network meta-analyses found that at six months subcutaneous tirzepatide was among the two agents associated with the largest weight change, alongside subcutaneous semaglutide, with effect sizes varying by dose arm [5]. The same review reported that no network meta-analysis had directly compared tirzepatide with the highest semaglutide dose at the time of the original search, that a later indirect comparison favoured the highest tirzepatide dose arm only, and that pooling across doses and time points limits interpretation [5]. It also reported that the agents associated with the largest weight change were generally associated with an increased risk of safety issues relative to placebo [5]. A narrative review of the two approved weekly agents summarised placebo-adjusted weight differences in human trials of people with overweight or obesity without diabetes as larger for tirzepatide than for semaglutide, and summarised trial reports of changes in cardiovascular outcomes, quality of life, heart-failure events in preserved ejection fraction, steatohepatitis and liver fibrosis endpoints, diabetes onset and treatment, renal function in chronic kidney disease, and obstructive sleep apnoea severity [6]. A narrative review focused on GIP biology reported that preclinical data on GIP receptor modulation in cardiac and renal tissue remain controversial, and that in the SURPASS-CVOT human trial tirzepatide met non-inferiority to dulaglutide for three-point major adverse cardiovascular events while slowing estimated GFR decline in participants at high chronic kidney disease risk [7]. The same review reported that in the SUMMIT human trial, conducted in individuals with obesity and heart failure with preserved ejection fraction, the composite endpoint of cardiovascular death or worsening heart failure events was reduced irrespective of baseline kidney function, and that the independent contribution of GIP receptor agonism to long-term cardiorenal endpoints remains unresolved pending ongoing trials [7]. Other narrative reviews of cardiovascular outcomes trials and heart-failure pharmacology describe tirzepatide within the obesity-related preserved-ejection-fraction phenotype, reporting improvements in symptoms and functional capacity and reductions in worsening heart-failure events, while noting that effects on cardiovascular mortality remain uncertain and that the available data derive from heterogeneous designs [8][9][10]. Mechanistic reviews place tirzepatide within gut-brain signalling, describing its action at GLP-1 and GIP receptors with effects attributed primarily to hypothalamic and brainstem pathways that reduce energy intake, and noting that human evidence on effects on reward-based eating is inconsistent [11]. A review of incretin signalling in non-alcoholic fatty liver disease discussed dual GIP and GLP-1 receptor agonism among incretin-receptor agonist strategies studied in relation to hepatic endpoints, drawing on mechanistic tissue data and randomised controlled trials [12]. Broader overviews of obesity pharmacotherapy list tirzepatide among agents associated with weight reduction and changes in lipid, glucose and central adiposity measures, and discuss cost, access, adherence and long-term uncertainty as open questions [13][14][15]. On the adverse-event side, a review of GLP-1 receptor agonist use in perioperative contexts reported gastrointestinal effects with increasing dose, along with reports of pancreatitis and bowel obstruction, and flagged venous thromboembolism and delayed gastric emptying as areas requiring further investigation in human populations [16]. A systematic review of hair-loss outcomes identified five primary studies covering 2,905 adults who received subcutaneous tirzepatide, mainly weekly, and reported conflicting findings, with some studies describing hair regrowth and others reporting hair loss as a dermatological adverse event; the authors concluded that further research is needed to clarify the relationship [17]. Earlier development-pipeline reviews situate tirzepatide among multiple incretin-based compounds then in clinical development for obesity, indicating that comparative long-term human data were still accumulating [18].